Navidea Biopharmaceuticals Announces $50 Million Credit

New Post Public Reply Private Reply Replies (0) Message Board

Aug 30, 2012 at 3:28 AM

Navidea Biopharmaceuticals Announces $50 Million Credit Facility with Platinum-Montaur Life Sciences

-Transaction provides flexible financial resources to fund short- and long-term development and growth plans-

DUBLIN, Ohio--(BUSINESS WIRE)--Jul. 26, 2012-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Platinum-Montaur Life Sciences, LLC (Montaur) will provide Navidea a credit facility of up to $50 million. This transaction provides the Company with significant, yet flexible, financial resources to fund its development and growth plans. No draws are currently planned in connection with entering into this facility.

Under the terms of the transaction, Montaur has committed to extend up to $15 million in debt, which is available immediately, to the Company at a prime-based interest rate currently at approximately 10 percent per annum. Montaur has committed an additional $20 million upon approval of Lymphoseek on consistent terms, with yet an additional $15 million potentially available on terms to be negotiated. No conversion features or warrants are associated with the facility.

Navidea is currently awaiting a response from the FDA on a New Drug Application that was submitted for Lymphoseek^® , its novel radiopharmaceutical imaging agent intended for use by surgeons in lymphatic mapping procedures associated with solid tumor cancers. Additionally, the Company’s pipeline includes the ongoing development of a number of diagnostic agents: AZD4694, a beta amyloid imaging agent for Alzheimer’s Disease; and RIGScan, a radio-labeled antibody diagnostic being studied in colorectal cancer.

Michael Goldberg, M.D., Principal, Montaur Capital Partners, LLC and Portfolio Manager of Montaur, said, “Navidea has been, and continues to represent, an excellent investment for Montaur. Our commitment to extend Navidea a non-dilutive credit facility is yet another sign of our confidence in Navidea, its expanding product pipeline and its management. We believe this transaction will support Navidea’s business and growth plans well through the launch period for Lymphoseek, by providing readily-available capital to support their business and pursue other desirable products and license opportunities that fit the Company’s aggressive strategy of pipeline development.”

Mark J. Pykett, V.M.D., Ph.D., Navidea’s President and CEO said, “We are energized by Montaur’s significant financial commitment and confidence in Navidea’s future. This transaction will provide us considerable flexibility to continue funding our growth as needed. Our financial partnership with Montaur has afforded us access to potential resources to confidently implement our plans to deepen our portfolio and advance our business as a leader in precision diagnostics.”

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek^® , AZD4694 and RIGScan^TM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com .

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company’s products are forward-looking statements within the meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

Source: Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc.
Sr. VP & CFO
Brent Larson, 614-822-2330

Navidea Biopharmaceuticals Inc. (NAVB) Stock Research Links

NAVB Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beyoncé Drops Remastered 'B'DAY'; Celebrates Legacy

Every so often, an artist comes around who's not just making music but shifting the very landscape of their genre. Beyoncé isn't just marking her birthday today; she's reminding the world of a career-defining moment with the release of her remastered deluxe version of 'B'DAY'. This isn't just a stroll down memory lane; it's a full-blown revival of an era that reshaped...

CRESYN Opens Model Residence: A Peek at City Living

CRESYN: Urban Elegance Hits Long Island City Who doesn't want to peek under the hood when a flashy new ride rolls into town? CRESYN's newly unveiled model residence in Long Island City is just that—an invitation to get up close and personal with what modern urban living can be. Forget the blueprints and glossy renderings. This place is the real deal, giving you that...

CreditRefresh's AI Tackles 1,000+ Disputes Launch Month

AI-Powered Revolution in Credit Disputes Alright, here we are staring down the latest twist in the credit game. CreditRefresh, an AI-driven platform out of Dover, Delaware, has managed to kickstart its journey by challenging over 1,000 credit report errors in just its first month on the market. That's quite a sprint straight from the gate, don't you think? But hey, this...

Wise Group Investors Alert Ahead of Key Legal Deadline

Sizing Up the Legal Stakes for Wise Group Alright, here's a doozy that's bound to get your attention if you've got a stake in Wise Group plc (NASDAQ: WSE). We're talking about a looming securities class action, with the deadline to get involved barreling down like a runaway freight train. Before September 29, 2026, to be exact—mark it, circle it, do whatever you have to...

PerfectVape Unveils Online Deals Amid Vape Craze

PerfectVape's Digital Bargain Bonanza Alright, so you think you've seen savings? Well, PerfectVape's throwing a real bone to those hunting for vape deals online. They're slapping 10% off on select disposable vapes—no strings, just a promo code, PV10, you punch in at checkout. We've got ourselves an internet-era sale without needing to elbow through crowds. Browsing Made...

Primero Gains Global Edge with Win Systems Buy

Here's the move: Primero Games, the U.S.-based gaming maestro, just grabbed a hefty piece of the puzzle with their acquisition of Win Systems' Gaming Division. Not two companies merging into obscurity, but a strategic maneuver aiming to scatter new seeds in Latin America and the Caribbean with over 3,000 gaming positions primed and ready. What's in the Pot? You've got...

What to Expect from KeyCorp at Barclays Event

KeyCorp's Next Move: An Insider's View Yep, circle that calendar, folks. Looks like KeyCorp's gonna be laying it all out there for the financial world to see. Clark Khayat, their numero uno money guy, is hitting the stage at the Barclays Global Financial Services Conference on Sept. 14. So grab the popcorn—or, more like, your portfolio tracker—because this could get...

Lyntris Advances KSAT Hyperion Satellite Program Milestone

Lyntris and KSAT: A Technological Feat in Space Connectivity Well, if it ain't Lyntris back in the headlines again, pushing the envelope on space connectivity. If you're keeping tabs on the space tech space, there's a cracker of a development brewing. Lyntris Inc. (NYSE: LYNX) just checked off a crucial box in their playbook—the Critical Design Review, or CDR for those...

PROCEPT Faces Legal Storm Over Sales Practices Missteps

Investors Take Aim: A Legal Showdown on the Horizon There's a brewing storm over at PROCEPT BioRobotics—ticker NASDAQ:PRCT if you're tracking. These folks are knee-deep in a securities class action lawsuit from investors who’ve taken a financial wallop. The lawsuits are triggered by allegations of shady sales techniques that artificially bumped up their unit sales...

Missouri American Water's $34.5M Neosho Acquisition Outline

Missouri American Water Expands in Neosho, Missouri Well, buckle up because Missouri American Water just sealed the deal to take over Neosho's water and wastewater systems. This acquisition cost them a cool $34.5 million and is bringing 5,400 water and another 5,400 wastewater customers into the fold. Plus, they're welcoming onboard 25 local workers who've been in the...